Anixa Biosciences (ANIX) Stock Price, Quote, News & History | Benzinga

Anixa Biosciences Inc (ANIX) Stock Price, Quote, News & History

ANIXNASDAQ

Trade with Public

Trade with Public

$3.71

0.123.34%

At close: Aug 21, 5:00 PM EST

$3.64

-0.07-1.89%

After Hours: 7:52 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$3.64

Close

$3.71

Volume / Avg.

182.55K / 233.42K

Day Range

$3.60 - $3.76

52 Wk Range

2.32 - 5.46

Market Cap

$123.84M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

60

Short Interest

3.39%

Days to Cover

3.67

Recent Anixa Biosciences Inc News

EXCLUSIVE: Anixa Biosciences' Ovarian Cancer Drug Candidate Shows Longer Survival With No Major Safety Issues

Anixa Biosciences shares new data from its ovarian cancer trial, showing patients lived longer than expected with no serious safety concerns, as regulators approved a major dose increase.

Vandana Singh

Anixa Biosciences Shares Jump Over 15% In After-Hours Trading — Here's Why

Anixa Biosciences shares surged in after-hours trading after presenting clinical trial data for its investigational breast cancer vaccine.

Mohd Haider

EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent

Anixa secures USPTO patent for its breast cancer vaccine using α-lactalbumin, enhancing its IP portfolio and expanding future immunotherapy options.

Vandana Singh

EXCLUSIVE: Anixa Biosciences Inks Letter of Intent with Austria-Based VERDI Solutions To Develop AI-Guided Personalized Cancer Vaccines

Anixa Biosciences signed a letter of intent with VERDI Solutions to develop AI-powered personalized and off-the-shelf cancer vaccines, with U.S. trials planned.

Vandana Singh

EXCLUSIVE: Anixa Biosciences Poised To Receive US Patent For Ovarian Cancer Vaccine

Anixa Biosciences secured a USPTO patent allowance for its ovarian cancer vaccine, strengthening its IP position and advancing its clinical development.

Vandana Singh

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-7.12M

Investing Cash Flow (TTM)

1.47M

Financing Cash Flow (TTM)

5.21M

Free Cash Flow (TTM)

-7.12M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-433.00K

Analyst Trends and Forecast

1

Mar

1

Apr

1

Jun

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$108.81M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

8.45

Earnings Yield % (TTM)

-8.34%

Earnings Yield % (FWD)

-9.18%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.43

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$1.48M

Debt to Equity

0.01

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$3.64

Close

$3.71

Volume / Avg.

182.55K / 233.42K

Day Range

$3.60 - $3.76

52 Wk Range

2.32 - 5.46

Market Cap

$123.84M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

60

Short Interest

3.39%

Days to Cover

3.67

About

Sector

Health Care

Industry

Biotechnology

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer V...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Anixa Biosciences (ANIX) stock?

A

You can purchase shares of Anixa Biosciences (NASDAQ:ANIX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Anixa Biosciences (ANIX) competitors?

A

Other companies in Anixa Biosciences’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Anixa Biosciences (ANIX) stock?

A

Anixa Biosciences has a consensus price target of $9.20.

Q

What is the current price for Anixa Biosciences (ANIX)?

A

The stock price for Anixa Biosciences (NASDAQ: ANIX) is $3.64 last updated August 21, 2026 at 7:52 PM EDT.

Q

Does Anixa Biosciences (ANIX) pay a dividend?

A

There are no upcoming dividends for Anixa Biosciences.

Q

When is Anixa Biosciences (NASDAQ:ANIX) reporting earnings?

A

Anixa Biosciences does not have any upcoming earnings scheduled.

Q

Is Anixa Biosciences (ANIX) going to split?

A

There is no upcoming split for Anixa Biosciences.

Q

What sector and industry does Anixa Biosciences (ANIX) operate in?

A

Anixa Biosciences is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.